Novo strengthened its pipeline rebuild through a preclinical business move, agreeing to pay $2.6 billion for rights tied to a GLP-1/GIP drug program from Hengrui. The transaction reflects continued consolidation around incretin therapies as developers pursue differentiated mechanisms, dosing advantages, and manufacturability across obesity and metabolic indications.